| Vol. 12.44 – 12 November, 2020 |
| |
|
|
| Using cell-based and mouse models of breast cancer together with clinical specimens, scientists showed that CDK4/6 inhibitors induced remodeling of cancer cell chromatin characterized by widespread enhancer activation. [Nature Cancer] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors describe a general strategy for in situ cancer vaccination that exploits both the immunogenic death of tumor cells and dendritic cell recruitment by biomaterial scaffolds. The strategy controlled 4T1 tumor growth and reduced metastases with minimal systemic toxicity, potentially providing a potent therapeutic option for TNBCs. [Nature Communications] |
|
|
|
| Researchers revealed that the most significant differences between Chinese and Western patients occurred in the hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer subtype. [Nature Communications] |
|
|
|
| Investigators found that neuropilin-1-targeted delivery of nucleus accumbens-associated protein-1 (NAC-1) siRNA mediated by tLyP-1 peptide-functionalized chimeric polymersomes effectively sensitized anti-angiogenic therapy of metastatic TNBC in vivo. [Biomacromolecules] |
|
|
|
| The authors found that cold-inducible RNA binding protein (CIRBP) transcript levels correlated with breast cancer subtype and was an indicator of luminal A/B prognosis. Accordingly, over-expression of CIRBP in non-tumoral MCF-10A cells promoted cell growth and clonogenicity, while depletion of CIRBP from luminal A MCF-7 cells had the opposite effects. [RNA] |
|
|
|
| Scientists clarified how coffee decoction exerts anti-cancer effects in cooperation with tamoxifen using the estrogen receptor α-positive breast cancer cell line, MCF-7. [Scientific Reports] |
|
|
|
| Researchers present two ex vivo models of tamoxifen-therapy, model one in which treatment recapitulated accumulation within breast tissue, by treating MCF7 and T47D cells directly prior to exposure to blood constituents; and model two in which they recreated circulating Tamoxifen by treating blood constituents prior to exposure to cancer cells. [Scientific Reports] |
|
|
|
| Scientists studied human breast cancer-derived cell-lines and a non-tumorigenic cell-line and compared their miRNA sequences at the spliceosome fraction. They report that the levels of miRNAs found in the spliceosome, their identity, and pre-miRNA segmental composition were cell-line specific. [International Journal of Molecular Sciences] |
|
|
|
| Using NT4 as an experimental tool mimicking heparin-binding ligands, researchers studied endocytosis and trafficking of heparan sulfate proteoglycan in a human TNBC cell line, MDA-MB-231. [International Journal of Molecular Sciences] |
|
|
|
|
| The authors describe the recent progress in the utilization of the circulating tumor components using early breast cancer samples. They also review the most important analytes and technologies employed for the study. [Ebiomedicine] |
|
|
|
| Understanding the genetic variability and also the non-genetic influences of tumor heterogeneity will provide novel insights into how to reverse therapeutic resistance and improve cancer therapy [Cancers] |
|
|
|
|
| Therapeutics Solution International, Inc. announced novel data supporting utilization of the company’s NanoStilbeneâ„¢ product for enhancement of cancer immunotherapy clinical trials. [Therapeutics Solution International, Inc. (PR Newswire Association, LLC.)] |
|
|
|
| eFFECTOR Therapeutics, Inc. announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase II study led by McGill University in Canada. [eFFECTOR Therapeutics, Inc. (Globe Newswire Inc.)] |
|
|
|
|
| April 11 – April 13, 2021 San Diego, California, United States |
|
|
|
|
|
| Pfizer – La Jolla, California, United States |
|
|
|
| University of North Dakota – Grand Forks, North Dakota, United States |
|
|
|
| Cancer Research UK Cambridge Institute – Cambridge, England, United Kingdom |
|
|
|
| IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
| University of Oslo – Oslo, Norway |
|
|
|
|